Cost-effectiveness of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

Kishan Patel,Stacey Stein,Janki Luther,Scott F. Huntington

Cost-effectiveness of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

2021

Kishan Patel
Stacey Stein
Janki Luther
Scott F. Huntington

e18829Background: The IMbrave150 trial found that atezolizumab and bevacizumab significantly prolonged progression-free survival (PFS) and overall survival (OS) in patients with locally advanced me...

Keywords:

Hepatocellular carcinoma
Internal medicine
Medicine
cost effectiveness
locally advanced
in patient
Bevacizumab
overall survival
Oncology
Atezolizumab

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations